BioAtla, Inc. BCAB 深 滬
已收盤 02-06 16:00:00 美东时间
0.2106
+0.021
+10.78%
華盛通- 最 高0.2238
- 今 開0.1933
- 成交量 299.32万股
- 最 低 0.1925
- 昨 收 0.1901
- 總市值 1348.69万
- 52周最高 1.43
- 市盈率 靜 --
- 換手率 4.67%
- 52周最低 0.14
- 委 比 -90.48%
- 總股本 6404.04万
- 歷史最高 76.63
- 量 比 0.57
- 振 幅 16.47%
- 歷史最低 0.14
- 每 手 1
- 風險率 0.20%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Monday's Intraday Session
Gainers AstraZeneca PLC Ordinary Shares (NYSE:AZN) stock rose 107.1% to $192.1...
02-03 01:05
BioAtla Inc. Announces Date for Upcoming Special Meeting of Stockholders
BioAtla Inc. Announces Date for Upcoming Special Meeting of Stockholders BioAtla Inc. has announced that it will hold a Special Meeting of Stockholders on [●], 2026. The meeting will be conducted entirely online via live webcast. During the meeting, stockholders will have the opportunity to submit q
01-31 06:14
BioAtla And GATC Health Announce $40M Special Purpose Vehicle Transaction, With $5M Initial Closing And Remaining $35M Expected In Q1 2026, To Fund Phase 3 Ozuriftamab Vedotin Registrational Trial In 2L+ OPSCC
BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026.BioAtla to retain 65%
2025-12-31 20:03
BioAtla Secures $7.5 Million Pre-Paid Advance
BioAtla ( ($BCAB) ) has issued an update. On November 20, 2025, BioAtla, Inc. e...
2025-11-21 19:43
BioAtla Secures $7.5M Advance And Up To $15M Standby Equity Commitment To Support Strategic Transaction
These agreements are designed to be a flexible financing solution to support operations while finalizing a strategic partnershipCompany is in advanced stages to finalize a strategic transaction with a potential partner,
2025-11-21 15:44
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers enGene Holdings (NASDAQ:ENGN) stock moved upwards by 3.5% to $7.12 dur...
2025-11-19 05:06
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
2025-11-13 19:11
BioAtla Presents Clinical Data In Poster Titled "Median OS Of 21.5 Months Among 44 Patients With Treatment-Refractory Leiomyosarcoma, Liposarcoma, And Undifferentiated Pleomorphic Sarcoma Treated With Mecbotamab Vedotin, An AXL-Targeting ADC," At SITC 2025
— Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with approved agents— Mec-V
2025-11-07 22:12
BioAtla Presents Ozuriftamab Vedotin Clinical Data Targeting ROR2 In HPV+ Head & Neck Cancer at IPVS Conference 2025
BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced
2025-10-23 20:17
